山大主页 | 山大药学院
 
 
 

教授
您现在的位置是: 首页 > 药物化学研究所 > 教授 > 正文

刘新泳 教授


undefined

、基本情况介绍

刘新泳,1963年3月生,山东平度人。博士,山东大学校聘二级岗教授,博士生导师,山东省医学领军人才,享受国务院政府特殊津贴;现任药学院院长,药物化学研究所所长,教研室主任;山东省新药设计与创新药物研究重点实验室主任;国家SFDA保健食品审评专家、国家科学技术奖励评审专家、科技部国际合作重点项目评审专家;山东省药学会理事、副秘书长;山东省药学会药物化学与抗生素专业委员会主任委员;中国药学会药物化学专业委员会委员。山东省卫生和计划生育委员会合理用药专家委员会副主任委员、山东省保健科技协会常务理事、山东省医学伦理学学会药学伦理学分会理事会副会长;国际杂志“Journal of Chemistry (IF 0.996)学术编辑(Academic Editor);国际著名期刊 Current Medicinal Chemistry (IF3.455)、Drug Discoveries & Therapeutics Medicinal chemistry(IF1.485)Interactive Medicinal ChemistryHans Journal of Medicinal Chemistry (HJMC)Edorium Journal of Drug Research Journal of Modern Medicinal ChemistryWorld Journal of Medicinal Chemistry、Letters in Drug Design & Discovery(IF 0.947)、Journal of Drug Design and Research、Journal of AIDS and HIV Infections、Current Research on HIV/AIDS、Drug Design Methodologies and Modern Medicinal Chemistry、Jacobs Journal of Organic Chemistry、Journal of Pharma & Pharmaceutical Sciences、Journal of Biochemistry and Molecular Biology ResearchWorld Journal of Virology World Journal of Clinical Infectious DiseasesVirology DiscoveryWorld Journal of PharmacologyJournal of Pharmacology & PharmacogenomicsPharmacologiaJournal of Chinese Pharmaceutical Sciences, Journal of Applied Pharmaceutical Research (JOAPR)编委;《中国药物化学杂志》、《中国医药工业杂志》、《山东大学学报(医学版)》、《中国药学-英文版》、《药学研究》、《山东化工》等编委。

联系方式: 山东大学药学院药物化学研究所, (济南市文化西路44  邮编250012) Tel. 086-531-88380270, Fax. 086-531-88382548E-mail: xinyongl@sdu.edu.cn

二、学习和工作经历

1980年考入山东医学院药学系,1984.7年毕业,获得学士学位,同年留校任教(1985.7助教)。1988.8年考入山东医科大学药物化学专业研究生,1991.7年毕业,获理学硕士学位。同年留校任教。1992.8年晋升讲师,1994.12年破格晋升为副教授、硕士导师。1997年3月—1999年3月,02年4-9月两度赴西班牙国家科学院药物研究所,作为访问教授从事国际合作课题研究,2001.9年晋升教授。2001.8年考入山东大学药物化学专业博士生,2004.6年获博士学位。2004年山东大学校聘关键岗教授,2009年山东大学校聘二级岗教授。

三、研究领域介绍

① 基于靶点的抗病毒药物的合理设计、合成与活性研究。本研究方向主要基于病毒(HIV、HBV、HCV和FluV)生命周期的分子生物学过程,针对病毒复制过程的关键酶或蛋白等靶点结构,通过计算机辅助,进行合理药物的设计、合成及抗病毒活性的研究。目前主要开展基于HIV-1逆转录酶的核苷类、非核苷类抑制剂研究;开展基于HIV-1侵入过程病毒gp120吸附抑制剂和辅助受体CCR5拮抗剂研究;开展基于HIV-1转录过程Tat-TAR相互作用、Rev-REE相互作用抑制剂的研究;整合酶抑制剂研究和多靶点药物研究。同时,开展基于HBV侵入、转录和包装过程的非核苷类抗乙肝病毒抑制剂研究;开展基于流感病毒神经氨酸酶、RNA聚合酶为靶点的抑制剂研究。

②基于凝血因子Xa结构的抑制剂研究。开展基于片段、药效团模型设计的抗凝血、抗血小板凝聚药物的研究。

③基于活性天然产物的结构修饰与心脑血管药理活性的研究。本研究方向主要开展中药川芎活性成分川芎嗪、川芎咔啉碱衍生物的结构修饰及其抗氧化损伤、抗凝血、抗血栓、抗血脂、抗缺血等心脑血管活性研究。

四、承担的主要课程

研究生:高等有机化学;有机化合物制备与分离技术。

本科生:生物有机化学;药学英语;无机化学等。

五、主要科研成果

近几年在 JMC; Eur J Med Chem.; Bioorg. Med. Chem. Lett; Bioorg. Med. Chem.; ChemMedChem; MedChemCom; Curr. Med.Chem; Curr Top Med Chem; Curr.Pharm.Des.; Fut. Med Chem.; Arch. Pharm; Arch Pharm Res; Curr HIV Res; Chem Biodive.; Antiviral Res.;Heterocycles; Molecules; Chemical Biology & Drug Design; Drug Futur;中国化学、有机化学、药学学报、中国药学杂志、中国药物化学杂志、中国医药工业杂志等发表文章200余篇;其中被SCI收录150余篇(第一和通讯作者,论文见附录);主编《抗艾滋病药物研究》专著(人民卫生出版社,北京,2006年12月)、主编《实验室有机化合物制备与分离技术》专著(人民卫生出版社,北京,2011年2月)、主编《无机化学》、 副主编《无机化学教程》教材;参编《分子核医学》、《现代生物医学示踪技术》(王世真院士主编) 等专著6部。曾荣获国家科技进步二等奖1项(第三,2015),山东省科技进步一等奖1项(第二,2012);山东省教育厅科技进步三等奖2项,山东省高等学校优秀科研成果奖一等奖2项(第一,2010、2016)、二等奖1项(第一,2005);申报国家发明专利50余项,其中已获得发明专利授权30余项;曾获2001山东省青年科技奖、2004山东省优秀中青年重点科技人才、2004年济南市青年科技明星奖、2002年山东大学优秀青年知识分子、2007年山东大学十大优秀教师、2009和2012年度山东大学优秀研究生指导教师,2009山东大学十大新闻人物提名奖、山东大学2012年度爱岗敬业十大模范人物,2010 山东省医学领军人才、2011获享受国务院政府特殊津贴、2012年获全国优秀百篇论文提名奖;201420152016年连续入选汤森路透社药理与毒理学研究领域“中国高引学者”等荣誉称号。

在药物开发与产业化方面:曾与企业合作,成功开发了头孢地嗪抗生素、抗心律失常药物尼非卡兰、抗菌药物奥硝唑分散片、抗病毒药物泰诺福韦酯原料及片剂、质子泵抑制剂埃索美拉唑、抗凝血药物替卡格雷等仿制药物,为企业创造了较大的经济和社会效益。

六、承担科研项目情况

1)含噻二嗪杂环新型碱基核苷酸类HIV逆转录酶抑制剂的设计、合成与活性研究。国家自然科学基金重点国际合作研究项目,项目编号: 814201080272015.1-2019.12, 课题主持人

2)新型六元芳杂环类抗耐药性HIV-1 NNRTI的设计、合成与活性研究. 国家自然基金,项目编号:81273354, 2013.01-2016.12  课题主持人

3)Design, synthesis and biological evaluation of heteroaryl substituted imidazole derivatives as potent Non-Nucleoside HBV Inhibitors--Research Fund for International Young Scientists (国家自然基金国外青年基金,项目编号: 2135011021520万,2013.0 7-2014.06  指导老师)。

4)新型HEPT类HIV-1非核苷类逆转录酶抑制剂的设计、合成与活性研究,国家自然基金重大国际合作项目,项目编号:  30910103908;  2010.01-2013.12  课题主持人

5). 三苯双咪国际合作项目,国家重大新药创制:山东省创新药物孵化基地建设,(2010ZX09401-302-3-1),2010.5-2013.5 (新华制药联合项目)

6)阿司匹林原料药技术改造,国家重大新药创制“125”第一批项目(2011ZX09203-001-01),2011.5-2014.5 (新华制药联合项目)

7) 新型抗耐药性HEPT类HIV-1非核苷类逆转录酶抑制剂的设计、合成与活性研究. 教育部博士点基金优先发展领域课题。项目编号: 20110131130005。 2011.1-2014.12, 主持人

8) 取代噻二嗪类HIV-1非核苷类逆转录酶抑制剂的设计合成及活性研究。 山东省自然基金,项目编号: ZR2009CM016  2010.1-2015.12  课题主持人

9)抗耐药流感病毒药物Favipiravir的研究.山东省科技发展计划,2014GSF1181752014.10-2016.10 课题主持人

10) 靶向于HIV-1多靶点蛋白gp120的非等同双靶点抑制剂研究. 国家自然基金-海外和港澳学者合作基金,30928031, 2010.01-2012.12, 国内课题主持人

11) 川芎嗪阿魏酸酯抗心脑血管疾病候选药物研究. 国家重大新药创制科技专项—候选药物,  2009ZX09103-117,科技部,2009.1-2012.1课题主持人

12) 取代噻二嗪类HIV-1非核苷类逆转录酶抑制剂的设计、合成与活性研究, 国家自然基金, 30873133;2009.1-2011.12. 课题主持人

13) 吡咯并噻三嗪类HIV-1非核苷类逆转录酶抑制剂的设计、合成与活性研究. 国家自然基金, 30772629,2008.01-2010.12. 课题主持人

14) 噻吩并噻二嗪新型非核苷类HIV逆转录酶抑制剂的研究. 国家自然基金30371686, 2004.1-2006.12. 课题主持人

15) 新型非核苷类HIV逆转录酶抑制剂的研究” 科技部国际合作重点项目, 303DF000033,2003.10-2006.12,50万;课题主持人

16) Synthesis and pharmacological evaluation of new quionoids compounds with potential therapeutic properties: antiviral and antitumor./新型蒽醌酮类化合物的合成及其抗病毒、抗肿瘤活性研究. 科技部中国-西班牙政府间国际合作课题Ref. Number 2002CN007,2002.1-2004.12;课题主持人

17) Synthesis And Pharmacological Evaluation Of New Heterocycles Containing The Thiocarbonyl groups/含硫杂环化合物的合成及其生物活性研究. Approved By The IV Joint Spanish-Chinese Commission Meeting Held In Beijing Sept. 1996. 科技部中国-西班牙政府间国际合作课题, 1997.1-1999.12, 课题主持人

18) 阿司匹林大品种技术改造,省科技厅自主创新项目(新华制药合作项目)100万,2013.06-2016.06

19)抗乙肝及艾滋病毒药物拉米夫定产业化技术,省科技厅自主创新项目,潍坊制药合作项目,90万,2013.07-2015.07

21)取代噻二嗪类HIV-1非核苷类逆转录酶抑制剂的设计合成及活性研究。山东省自然基金,项目编号: ZR2009CM016  经费 5万元, 2010.1-2012.12  课题主持人

22)取代吡咯并噻三嗪新型非核苷类HIV-1 NNRTIs的设计、合成与活性研究,教育部博士点基金,6万 项目编号: 20070422083, 2008.1-2010.12  课题主持人

23)川芎嗪烟酸酯新型心血管药物的合成与开发 2006GG2202063 ,山东省科技发展计划 9万 2007-2009 山东省科技厅,课题主持人

七、获得授权专利

1.刘新泳, 徐文方 等,川芎醇酯类衍生物及其制备方法和含有川芎醇酯类衍生物的药物组合物与应用。中国发明专利, ZL02135989.X , 中华人民共和国国家知识产权局,2005-1-12

2.刘新泳,徐文方, 程先超 等 川芎嗪烃基哌嗪类衍生物、制备方法和药物组合物与应用。 中华人民共和国国家知识产权局, 中国发明专利,专利号:ZL200510045307.4,(2007-7-18)

3.刘新泳,徐文方, 闫任章 等. 2,4-二取代杂环并[4,5-e][1,2,4]噻二嗪衍生物制备方法. 中华人民共和国国家知识产权局。专利号:ZL2006 1 0043834.6  2008-6-11

4. 刘新泳,徐文方, 闫任章 等.  N4-取代吡唑[4,5-e]]1,2,4]噻二嗪类衍生物、制备方法及其药物组合物与应用。 中华人民共和国国家知识产权局。专利号:ZL200510044297.2  2009-5-6

5. 刘新泳,徐文方, 林永强 等.  N1,N3-二取代噻吩并[3,2-e][2,1,3]噻二嗪-2,2,4-三酮类衍生物与应用。中华人民共和国国家知识产权局。专利号:ZL 200610043833.1, 2009年6月17日

6. 刘新泳,李锦 等.  N1,N3-二取代吡唑并[4,5-e][2,1,3]噻二嗪-2,2,4-三酮类衍生物及其制备方法与应用。专利号:ZL200710015052.6  中华人民共和国国家知识产权局,2009年7月29

7. 刘新泳, 常昱 等. 聚乙二醇修饰齐夫多定缀合物及其制备方法与应用,中华人民共和国国家知识产权局,专利号: ZL200710015587.3,   授权日:2010-1-21 。

8.刘新泳,邓利娟 等, 川芎嗪茋类衍生物、制备方法和药物组合物与应用。中华人民共和国国家知识产权局,专利号: ZL200710014906.9, 授权日:2010-2-03

9. 刘新泳,于芳 等, 川芎嗪胍类衍生物的制备方法及其应用。中华人民共和国国家知识产权局。专利号: ZL200810157518.0,  授权日:2010-06

10. 刘新泳,于芳等. 川芎嗪酰胺类衍生物、制备方法和药物组合物与应用。专利号:ZL200810157251.5, 授权日:2011-3-16

11. 刘新泳, 展鹏等. 1,2,3-噻二唑巯乙酰胺类衍生物及其制备方法。专利号:ZL200910016414.2,授权日:2011-2-16

12. 刘新泳, 于明艳等. 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3H-嘧啶-4-酮类衍生物及其制备方法与应用 ZL200910017725.0,授权日:2011.4.27

13. 刘新泳, 展鹏等. N-取代苯基-2-(1-芳基-1H-咪唑-2-巯基)乙酰胺类衍生物及其制备方法与应用. 专利号:ZL200810157250.0  授权日: 2011-4-27

14.刘新泳, 展鹏, 方增军.  1,2,3-硒二唑巯乙酰胺类衍生物及其制备方法与应用。发明专利专利号:ZL200910016413.8,授权日: 2011-6-15

15. 刘新泳, 展鹏, 方增军,李震宇. 取代噻唑巯乙酰胺类衍生物及其制备方法与应用。发明专利,专利号:ZL201010223400.0,授权日: 2012-7-25

16. 刘新泳, 展鹏, 方增军。2-(2-取代芳基-2H-1,2,4-三唑-3-巯基)乙酰胺衍生物及其制备方法与应用,发明专利,专利号:ZL201010223401.5,授权日: 2012-7-25

17. 刘新泳,李震宇,展鹏。5-取代-2-(4-取代苯基)苯并噁唑类衍生物及其制备方法与应用。发明专利,专利号:ZL201110021056.1, 授权日:2012-10- 3

18. 刘新泳,陈绪旺,展鹏。N1-取代哌啶-4-芳胺类衍生物及其制备方法与应用。发明专利,专利号:ZL201110177402.5,授权日: 2013-6-19

19. 刘新泳,展鹏. 六元芳杂环并咪唑巯乙酰胺类衍生物及其制备方法与应用. 发明专利,专利号:ZL 201110394885.4, 2013-08-28

20. 刘新泳,陈文敏。 N2,N4-双取代-2H,4H-吡咯[1,2-b][1,2,4,6]噻三嗪-1,1,3-三酮衍生物及其制备与应用 。ZL 201110202340.9, 2013-11

21. 刘新泳,展鹏等。一种哒嗪类HIV-1逆转录酶抑制剂的制备与应用,国家发明专利(专利号ZL201210234354.3),2014-07-30

22. 刘新泳,刘涛。一种取代噻二嗪三酮类衍生物及其制备方法与应用。发明专利, ZL 2013104332764,2014-12-10

23. 刘新泳,展鹏等,5-芳基-1,2,3-噻二唑-4-巯基乙酰胺类衍生物及其制备方法和应用,国家发明专利(专利号ZL201210146323.2)2014-05-21

24. 刘新泳,李文军等,(2-(3-甲硫基-1,2,4-噻二嗪)乙氧基)甲基膦酸酯类衍生物及其制备与应用。国家发明专利(专利号ZL201210330875.9),2014-10-22

25. 刘新泳,陈绪旺等,三嗪巯乙酰胺类衍生物及其制备方法与应用。国家发明专利(专利号ZL201210351689.3),2014-12-17

26. 刘新泳,田野,展鹏。一种取代噻二嗪类衍生物及其制备方法与应用。国家发明专利(专利号ZL201210262075. 8),2015-1-21

27. 刘新泳等。一种三唑并嘧啶类HIV-1逆转录酶抑制剂及其制备方法与应用,国家发明专利ZL 201310309821.9 , 2015.3

28. 刘新泳等。一种芳杂氧乙酰肼类衍生物及其制备方法与应用,国家发明专利:ZL2013103098100,2015

29. 刘新泳,陈洪飞。川芎嗪甲酰氧基肉桂酸类衍生物及其制备方法与应用.发明专利证书ZL201210297075.1, 2015年11月18日,

30. 刘新泳等。一种2,4,6-三取代嘧啶衍生物及其制备方法与应用,ZL201310433416.8,国家发明专利,2015.4

31. 一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用,国家发明专利, ZL 201310560652.6,2015.12

32.刘新泳,陈洪飞.噻唑-4-甲酰基哌嗪衍生物及其制备方法与应用. 国家发明专利,, ZL201410268548.4,  2016

33. 刘新泳,张凌子. 2-(N-芳甲基哌啶-4-氨基)-4-(取代苯酚)苯环衍生物及其制备方法与应用. 国家发明专利, ZL201310452018.0,  2016

34.刘新泳,陈洪飞. N-(2-(胺甲基)苯基)噻唑-4-甲酰胺衍生物及其制备方法与应用. 国家发明专利, ZL201410267280.2,  2016

35. 刘新泳,刘涛,展鹏. 一种取代噻二嗪二酮类衍生物及其制备方法与应用. 国家发明专利, ZL201410264693.5, 2016

36. 刘新泳,刘涛,展鹏. 嘧啶巯乙酰胺类衍生物及其制备方法与应用. 国家发明专利, ZL201410276055.5, 2016

37.刘新泳,康东伟,展鹏,方增军. 一种依曲韦林的制备方法. 国家发明专利, ZL201410699294.1, 2016

38. 刘新泳,梁鑫,展鹏. 一种咪唑并吡嗪类衍生物及其制备方法与应用. 国家发明专利, ZL201410276052.1, 2016

八、发表论文

2017年

Xiao Li, Ping Gao, Boshi Huang, Zhongxia Zhou, Zhao Yu, Zheng Yuan, Huiqing Liu, Christophe Pannecouque, Dirk Daelemans, Erik De Clercq, Peng Zhan, Xinyong Liu. Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. European Journal of Medicinal Chemistry; 2017( 126): 190-201

2016年

1.  Kang, Dongwei; Fang, Zengjun; Li, Zhenyu; Huang, Boshi; Zhang, Heng; Lu, Xueyi; Xu, Haoran; Zhou, Zhongxia; Ding, Xiao; Daelemans, Dirk; De Clercq, Erik; Pannecouque, Christophe*; Zhan, Peng*; Liu, Xinyong*. Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. J Med Chem. 2016, 59(17):7991-8007.

2.  Zhan, Peng; Pannecouque, Christophe; De Clercq, Erik*; Liu, Xinyong*. Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. J Med Chem. 2016, 59(7):2849-78.

3.  Chen, Wenmin; Zhan, Peng; Daelemans, Dirk; Yang, Jiapei; Huang, Boshi; De Clercq, Erik; Pannecouque, Christophe*; Liu, Xinyong*. Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. Eur J Med Chem. 2016, 121:352-63.

4.  Yang, Jiapei; Chen, Wenmin; Kang, Dongwei; Lu, Xueyi; Li, Xiao; Liu, Zhaoqiang; Huang, Boshi; Daelemans, Dirk; Pannecouque, Christophe; De Clercq, Erik; Zhan, Peng*; Liu, Xinyong*. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. Eur J Med Chem. 2016, 109:294-304.

5.  Jia, Haiyong; Bai, Fuxiang; Liu, Na; Liang, Xiaohong; Zhan, Peng; Ma, Chunhong;  Jiang, Xuemei; Liu, Xinyong*. Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors. Eur J Med Chem. 2016, 123:202-10.

6.  Meng, Qing; Chen, Xuwang; Kang, Dongwei; Huang, Boshi; Li, Wenxin; Zhan, Peng; Daelemans, Dirk; De Clercq, Erik; Pannecouque, Christophe*; Liu, Xinyong*. Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. Eur J Med Chem. 2016, 115:53-62.

7.  Li, Xiao; Gao, Ping; Huang, Boshi; Zhou, Zhongxia; Yu, Zhao; Yuan, Zheng; Liu, Huiqing; Pannecouque, Christophe; Daelemans, Dirk; De Clercq, Erik; Zhan, Peng*; Liu, Xinyong*. Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. Eur J Med Chem. 2016;126:190-201.

8.  Kang, Dongwei; Zhang, Heng; Zhou, Zhongxia; Huang, Boshi; Naesens, Lieve*; Zhan, Peng*; Liu, Xinyong*. First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach. Bioorg Med Chem Lett. 2016, 26(21):5182-6.

9.  Lu, Xueyi; Li, Xiao; Yang, Jiapei; Huang, Boshi; Kang, Dongwei; Zhao, Fabao; Zhou, Zhongxia; De Clercq, Erik; Daelemans, Dirk; Pannecouque, Christophe*; Zhan, Peng*;  Liu, Xinyong*. Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. Bioorg Med Chem. 2016, 24(18):4424-33.

10.     Li, Wenxin; Huang, Boshi; Kang, Dongwei; De Clercq, Erik; Daelemans, Dirk; Pannecouque, Christophe; Zhan, Peng*; Liu, Xinyong*. Design, synthesis, and biological evaluation of novel 5-Alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones as HIV-1 non-nucleoside reverse- transcript- tase inhibitors. Chem Biol Drug Des. 2016, 88(3):380-5.

11.     Li, Xiao; Huang, Boshi; Zhou, Zhongxia; Gao, Ping; Pannecouque, Christophe; Daelemans, Dirk; De Clercq, Erik; Zhan, Peng*; Liu, Xinyong*. Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach. Chem Biol Drug Des. 2016, 88(2):241-53.

12.     Huang, Boshi; Li, Xiao; Zhan, Peng*; De Clercq, Erik; Daelemans, Dirk; Pannecouque, Christophe; Liu, Xinyong*. Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents. Chem Biol Drug Des. 2016, 87(2):283-9.

13.     Xu, Haoran; Fu, Lu; Zhan, Peng*; Liu, Xinyong*. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA. SAR QSAR Environ Res. 2016, 1-16.

14.     Sun, Lin; Gao, Ping; Zhan, Peng*; Liu, Xinyong*. Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182. Expert Opin Ther Pat. 2016, 26(9):979-86.

15.     Gao, Ping; Sun, Lin; Zhou, Junsu; Li, Xiao; Zhan, Peng*; Liu, Xinyong*. Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach. Expert Opin Drug Discov. 2016, 11(9):857-71.

16.     Zhang, Heng; Kang, Dongwei; Huang, Boshi; Liu, Na; Zhao, Fabao; Zhan, Peng*; Liu, Xinyong*. Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities. Eur J Med Chem. 2016, 114:65-78.

17.     Li, Xiao; Gao, Ping; Zhan, Peng*; Liu, Xinyong*. Substituted indoles as HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent evaluation (WO2015044928). Expert Opin Ther Pat. 2016, 26(5):629-35.

18.     Huang, Boshi; Kang, Dongwei; Yang, Jiapei; Zhan, Peng*; Liu, Xinyong*. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. Expert Opin Ther Pat. 2016, 26(2):281-9.

19.     Huang, Boshi; Zhou, Zhongxia; Kang, Ddongwei; Li, Wanzhuo; Chen, Zihui; Zhan, Peng*; Liu Xinyong*. Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2). Expert Opin Ther Pat. 2016 Nov 25:1-7.

20.     Wang, Xueshun; Huang, Boshi; Liu, Xinyong*; Zhan, Peng*. Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries. Drug Discov Today. 2016, 21(1):118-32.

21.     Zhan, Peng; Wang, Xueshun; Liu, Xinyong*; Suzuki, Takayoshi*. Medicinal chemistry insights into novel HDAC inhibitors: An updated patent review (2012-2016). Recent Pat Anticancer Drug Discov. 2016.

22.     Huang, Boshi; Liu, Xinhao; Li, Wanzhuo; Chen, Zihui; Kang, Dongwei; Zhan, Peng*; Liu, Xinyong*. An improved synthesis approach of the HIV-1 inhibitor RDEA427, a pyrrolo[2,3-d]pyrimidine derivative. ARKIVOC. 2016;6:45 - 51.

23. Zhan Peng, Wang Xueshun, Liu Xinyong. Contemporary Molecular Targeted Drug in the Context of “Precision Medicine”: An Attempting Discussion of “Precision Drug Design”. Progress in Chemistry, 2016, 28(9): 1363-1386

2015年

1. Zhan, Peng; Itoh, Yukihiro; Suzuki, Takayoshi*; Liu, Xinyong*. Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators. J Med Chem 2015, 58, 7611-33.

2. Boshi Huang; Cuicui Li; Wenmin Chen; Tao Liu; Mingyan Yu; Lu Fu; Yueyue Sun; Huiqing Liu; Erik De Clercq; Christophe Pannecouque; Jan Balzarini; Peng Zhan; Xinyong Liu*. Fused Heterocycles Bearing Bridgehead Nitrogen as Potent HIV-1 NNRTIs. Part 3: Optimization of [1,2,4]Triazolo[1,5-a]pyrimidine Core via Structure-based and Physicochemical Property-driven Approaches. European Journal of Medicinal Chemistry. 2015;92:754-765 (DOI information: 10.1016/j.ejmech.2015.01.042)

3. Boshi Huang; Xin Liang; Cuicui Li; Wenmin Chen, Tao Liu; Xiao Li; Yueyue Sun; Lu Fu; Huiqing Liu, Erik De Clercq, Christophe Pannecouque, Peng Zhan*, Xinyong Liu*. Fused Heterocycles Bearing Bridgehead Nitrogen as Potent HIV-1 NNRTIs. Part 4: Design, Synthesis and Biological evaluation of Novel Imidazo[1,2-a]pyrazines. European Journal of Medicinal Chemistry, 2015; 93: 330-337. (doi: 10.1016/j.ejmech.2015.02.022)

4. Yu’ning Song, Hao Xu, Wenmin Chen, Peng Zhan,*, Xinyong Liu* 8-Hydroxyquinoline: A Privileged Structure with Broad-ranging Pharmacological Potentials. Medicinal Chemistry Communications. 2015; 6: 61-74

5. Tao Liu, Boshi Huang, Ye Tian, Xin Liang, Hong Liu, Huiqing Liu, Peng Zhan*, Erik De Clercq, Christophe Pannecouque and Xinyong Liu*. Design, Synthesis, and Biological Evaluation of Novel 4-Aminopiperidinyl-linked 3,5-Disubstituted-1,2,6-thiadiazine-1,1-dione Derivatives as HIV-1 NNRTIs. Chemical Biology & Drug Design , Chem Biol Drug Des, 2015; 86, 107-13.

6. Xuwang Chen, Qing Meng, Peng Zhan, Huiqing Liu, Erik De Clercq, Christophe Pannecouque and Xinyong Liu*. Design, Synthesis and Anti-HIV Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the NNRTI Binding Pocket. Chemical Biology & Drug Design. 2015; 86, 122-8.

7. Zengjun Fang, Dongwei Kang, Lingzi Zhang, Boshi Huang, Huiqing Liu, Christophe Pannecouque, Erik De Clercq, Peng Zhan* and Xinyong Liu*. Synthesis and Biological Evaluation of a Series of 2-((1-substituted-1H-1,2,3-triazol-4-yl)methylthio)-6-(naphthalen-1- ylmethyl)pyrimidin-4(3H)-one As Potential HIV-1 Inhibitors Chemical Biology & Drug Design. 2015; 86, 614-8.

8. Zhang, Lingzi; Guo, Jian; Liu, Xin; Liu, Huiqing; De Clercq, Erik; Pannecouque, Christophe; Liu, Xinyong*. Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents. Chem Biol Drug Des 2015, 86, 333-43.

9.Kang, Dongwei; Fang, Zengjun; Huang, Boshi; Zhang, Lingzi; Liu, Huiqing.; Pannecouque, Christophe; Naesens, Laesens; De Clercq, Erik; Zhan, Peng; Liu, Xinyong*. Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections. Chem Biol Drug Des 2015, 86, 568-77.

10. Diwakar Rai, Liu Wang, Xuemei Jiang*, Peng Zhan, Haiyong Jia, Erik De Clercq, and Xinyong Liu* The changing face of Hepatitis C: Recent Advances on HCV Inhibitors Targeting NS5A. Current Medicinal Chemistry, 2015; 22(15): 1860-1879.

11. Wang Xueshun, Huang Boshi, Suzuki Takayoshi*, Liu Xinyong*; Zhan Peng*. Medicinal chemistry insights in the discovery of novel LSD1 inhibitors. Epigenomics 2015; 7, 1379-96.

12. Na Liu, Fabao Zhao, Haiyong Jia, Diwakar Rai, Peng Zhan*, Xuemei Jiang* and Xinyong Liu*. Non-nucleoside anti-HBV agents: Advances in structural optimization and mechanism of action investigations. MedChemComm. 2015; 6( 4): 521-535

13. Fabao Zhao, Na Liu, Peng Zhan*, Xuemei Jiang* and Xinyong Liu*. Discovery of HCV NS5B Thumb Site I Inhibitors: Core-refining from Benzimidazole to Indole Scaffold. European Journal of Medicinal Chemistry. 2015; 94: 218-228, EJMECH-D-14-02281R1

14. Haiyong Jia, Diwakar Rai, Xuwang Chen, Peng Zhan*, Xuemei Jiang,* and Xinyong Liu*. Recent Advance of the Hepatitis B Virus Inhibitors: a Medicinal Chemistry Overview. Future Medicinal Chemistry, 2015; 7(5):587-607. doi: 10.4155/fmc.15.19

15. Na Liu, Fabao Zhao, Peng Zhan and Xinyong Liu*. Review of Small Synthetic Molecules Targeting HBV Capsid Assembly. Medicinal Chemistry. 2015;11(8):710-716, DOI: 10.2174/157340641108151029111243

16. Liu, Xin; Chen, Xuwang; Zhang, Lingzi; Zhan, Peng; Liu, Xinyong*. 3D-QSAR and docking studies on piperidine-substituted diarylpyrimidine analogues as HIV-1 reverse transcriptase inhibitors. Med Chem Res. 2015; 24: 3314-3326

17. Li, Wenlong; Liu, Huiqing; Wei, Chunmin; Wei, Xinbing; Tang, Mingtian; Kong, Xianlin; Chen, Hongfei; Liu, Xinyong; Guo, Ruichen*. Pharmacokinetics and metabolism of Chf197, a ligustrazine derivative, in rats. Fundam Clin Pharmacol 2015, 29, 478-87.

18.Yan, Shi; Chen, Lin; Wei, Xinbing; Cheng, Li; Kong, Lingjun; Liu, Xinyong; Zhang, Xiumei.; Liu, Huiqing. Tetramethylpyrazine analogue CXC195 ameliorates cerebral ischemia-reperfusion injury by regulating endothelial nitric oxide synthase phosphorylation via PI3K/Akt signaling. Neurochem Res 2015, 40, 446-54.

19. Zhao Fabao, Liu Na, Zhan Peng*, Jiang Xuemei*, Liu Xinyong*. Discovery of HCV NS5B thumb site I inhibitors: core-refining from benzimidazole to indole scaffold. Eur J Med Chem 2015, 94, 218-28.

20. Wenxin Li, Xiao Li, Erik De Clercq, Peng Zhan, Xinyong Liu*. Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif. European Journal of Medicinal Chemistry. 2015; 102:167-179

21. Qing Meng, Na Liu, Boshi Huang, Peng Zhan* & Xinyong Liu*. Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419. Expert Opin Ther Pat 2015; 25, 1477-86.

22. Boshi Huang, Kang Dongwei, Zhan Peng*, Liu Xinyong*. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities. Expert Opin Drug Discov 2015; 10, 1271-81.

23.Xinyong Liu. Meet the Editorial Board Member, Letters in Drug Design & Discovery, 2015; 12: 519 - 520

2014年

1. Yuanchao Xie, Dongqing Xu, Bing Huang, Xiuli Ma, Wenbao Qi, Fangyuan Shi, Xinyong Liu,*, Yingjie Zhang*, and Wenfang Xu*.  Discovery of NSubstituted Oseltamivir Derivatives as Potent and Selective Inhibitors of H5N1 Influenza Neuraminidase. Journal of Medicinal Chemistry, 2014, 57 (20): 8445–8458

2. Liu Wang, Ye Tian, Wenmin Chen, Hong Liu, Peng Zhan, Dongyue Li, Huiqing Liu, Erik De Clercq, Christophe Pannecouque, Xinyong Liu*. Fused Heterocyclic Compounds Bearing Bridgehead Nitrogen as Potent HIV-1 NNRTIs. Part 2: Discovery of Novel [1,2,4]Triazolo[1,5-a] pyrimidines Using A Structure-guided Core-refining Approach. European Journal of Medicinal Chemistry, 201485:293-303

3. Tao Liu, Boshi Huang, Peng Zhan, Erik De Clercq, Xinyong Liu*. Discovery of small molecular inhibitors targeting HIV-1 gp120–CD4 interaction derived from BMS-378806. European Journal of Medicinal Chemistry, 201486: 481-490

4. Jun Wang, Peng Zhan, Zhenyu Li, Huiqing Liu, Erik De Clercq, Christophe Pannecouque, Xinyong Liu*. Nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry. 2014, 76 (9 April): 531–538

5. Xiao Li, Wenmin Chen, Ye Tian, Huiqing Liu, Peng Zhan, Erik De Clercq, Christophe Pannecouque, Jan Balzarini, Xinyong Liu*. Discovery of Novel Diarylpyrimidines as Potent HIV NNRTIs via A Structure-guided Core-refining Approach. European Journal of Medicinal Chemistry, 2014; 80: 112-121.

6. Yu’ning Song, Xiaoqian Lin, Dongwei Kang, Xiao Li, Peng Zhan*, Xinyong Liu*, Qingzhu Zhang*, Discovery and Characterization of Novel Imidazopyridine Derivative CHEQ-2 as A Potent CDC25 Inhibitor and Promising Anticancer Drug Candidate. European Journal of Medicinal Chemistry. 2014; 82: 293-307.

7. Liu Zhaoqiang, Wenmin Chen, Peng Zhan*, Erik De Clercq, Christophe Pannecouque, Xinyong Liu*. Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided hybridization", European Journal of Medicinal Chemistry, 2014; 87: 52-62

8. Xiao Li, Xueyi Lu, Wenmin Chen , Huiqing Liu , Peng Zhan*, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu*. Arylazolyl(azinyl)thioacetanilides. Part 16☆: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors. Bioorganic & Medicinal Chemistry. 2014; 22(19): 52905297.

9. Lingzi Zhang, Peng Zhan, Xuwang Chen, Zhenyu Li, Zhoumeng Xie, Tong Zhao, Huiqing Liu, Erick De Clercq, Christophe Pannecouque, Jan Balzarini and Xinyong Liu*. Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. Reference: Bioorganic & Medicinal Chemistry .2014; 22: pp. 633-642

10. Wenmin Chen, Peng Zhan, Diwakar Rai, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Huiqing Liu, Zhongxia Zhou, Xinyong Liu*. Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays. Bioorganic & Medicinal Chemistry, 2014; 22: 1863-1872

11. Ye Tian, Deping Du, Diwakar Rai, Liu Wang, Huiqing Liu, Peng Zhan,*, Erik De Clercq, Christophe Pannecouque, Xinyong Liu,*. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: Design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. Bioorganic & Medicinal Chemistry, 2014; 22: 2052-2059

12. Hongfei Chen; Guoning Li, Qian Ding; Lei Cui, Peng Zhan, Shouxun Wang, Xinyong Liu* Design, synthesis and biological evaluation of novel trimethylpyrazine-2-carbonyloxy-cinnamic acids as potent cardiovascular agents. Medicinal Chemistry Communications., 2014, 5, 711-718

13. Diwakar Rai, Wenmin Chen, Peng Zhan, Hong Liu, Ye Tian, Xin Liang, Erik De Clercq, Christophe Pannecouque, Jan Balzarini, and Xinyong Liu*. Synthesis and Anti-HIV Activity of 4-(Naphthalen-1-yl)-1,2,5-thiadiazol-3-hydroxyl Derivatives. Chemical Biology & Drug Design, 2014; 84: 420–430

14. Zengjun Fang, Yu’ning Song, Qingzhu Zhang, Peng Zhan* & Xinyong Liu*. Conformational restriction: an effective tactic in 'follow-on'-based drug discovery. Future Medicinal Chemistry. 2014; 6(8):885-901.

15. Zhenyu Li, Fang Yu, Lei Cui, Wenmin Chen, Shouxun Wang, Peng Zhan, Yuemao Shen and Xinyong Liu*. Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents. Medicinal Chemistry. 2014; 10( 1): 81-89

17. Jun Wang, Yan Wang, Rujun Bai, Peng Zhan, Christophe Pannecouque Jan Balzarini, Erik De Clercqb, Xinyong Liu*. Design, Synthesis and Biological Evaluation of Substituted Guanidine Indole Derivatives as Potential Inhibitors of HIV-1 Tat-TAR Interaction. Med Chem. 2014;10(7):738-46.

17. Yu’ning Song, Zengjun Fang, Peng Zhan and Xinyong Liu*. Recent Advances in the Discovery and Development of Novel HIV-1 NNRTI Platforms (Part II): 2009-2013 Update#. Current Medicinal Chemistry. 2014; 21(3): 329-355.

18. Lili Cao, Peng Zhan*, Weiguo Song, Erik De Clercq, and Xinyong Liu*. Recent progress in the research of small molecule HIV-1 RNase H inhibitors. Current Medicinal Chemistry. 2014; 21(17): 1956-1967

19. Ye Tian, Dujuan Zhang, Peng Zhan and Xinyong Liu*. Medicinal Chemistry of Small Molecule CCR5 Antagonists for Blocking HIV-1 Entry: A Review of Structural Evolution. Current Topics in Medicinal Chemistry (CTMC). 2014;14(13):1515-1538

20. Xiao Li, Lingzi Zhang, Ye Tian, Yu’ning Song, Peng Zhan, and Xinyong Liu*. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011–2014). Expert Opin Ther Pat. 2014; 24(11): 1199-227  (doi:10.1517/13543776.2014.964685)

21. Yu’ning Song, Wenmin Chen, Dongwei Kang, Peng Zhan* and Xinyong Liu*. “Old Friends in New Guise”: Exploiting Privileged Structures for Scaffold Re-Evolution/Refining. Combinatorial Chemistry & High Throughput Screening, 2014, 17(6): 536-53.

22. Dongwei Kang, Yu’ning Song, Wenmin Chen, Peng Zhan*, Xinyong Liu* . “Old Dogs with New Tricks”: Exploiting Alternative Mechanisms of Action and New Drug Design Strategies for Clinically Validated HIV Targets. Molecular BioSystems, 2014; 10(8): 1998-2022.

Impact Factor: 3.35). 05/2014; DOI:10.1039/c4mb00147h.

23. Zhan Peng*, Song Yunning, Itoh Y, Suzuki T*, Liu Xinyong*. Recent advances in the structure-based rational design of TNKSIs. Molecular Biosyst. 2014, 10(11): 2783-2799.

24. Lin Chen, Xinbing Wei, Yunfeng Hou, Xiaoqian Liu, Senpeng Li, Baozhu Sun, Xinyong Liu, Huiqing Liu. Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion-induced apoptosis through PI3K/Akt/GSK3β pathway in rats. Neurochemistry International. 2014; 66(1): 27-32  (Impact Factor 2.66)

25. Chen J, Wang W, Wang H, Liu X, Guo X. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis. Drug Discov Ther. 2014; 8(1): 33-41.

26. Zhang, Peng*; Zheng, Bei-Bei; Wang, Hong-Yuan; Chen, Jin-Hua; Liu, Xin-Yong*; Guo, Xiu-Li*, DLJ14, a novel chemo-sensitization agent, enhances therapeutic effects of adriamycin against MCF-7/A cells both in vitro and in vivo, Journal of Pharmacy and Pharmacology, 66(3), pp 398-407, 2014/3.

2013

1. Wenjun Li, Peng Zhan, Erik De Clercq, Hongxiang Lou*, Xingyong Liu*. Current Drug research on PEGytion with small molecular agents. Progress in Polymer Science, 2013; 38: 421-444. (IF= 26.383)

2. Peng Zhan, Xuwang Chen, Dongyue Li, Zengjun Fang, Erik De Clercq, Xinyong Liu*. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. Medicinal Research Review, 2013; 33(S1): E1-E72  (IF=9.583)

3. Ye Tian, Diwakar Rai, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Huiqing Liu, Xinyong Liu*. Design, synthesis and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs (CBDD-RA-02-13-1571) . Chemical Biology & Drug Design. 2003: 82(4):384-93

4. Wenmin Chen, Peng Zhan, Erik De Clercq, Christophe Pannecouque, Jan Balzarini, Xin Jiang, Xinyong Liu*. Design, synthesis and biological evaluation of N2, N4-disubstituted- 1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry. 2013; 21(22):7091-7100

5. Diwakar Rai,Wenmin Chen, Ye Tian, Xuwang Chen,Peng Zhan, Erik De Clercq, Christophe Pannecouque, Jan Balzarinib, Xinyong Liu*. Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry. 2013; 21: 7398–7405 (Reference: BMC11135)

6. Dongyue Li, Peng Zhan, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu*. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry. 2013; 21(7): 2128-2134.

7. Yu’ning Song, Peng Zhan,* Dongwei Kang, Xiao Li, Ye Tian, Zhenyu Li, Xuwang Chen,   Wenmin Chen, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Discovery of novel pyridaziylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach. Medicinal Chemistry Communications. 2013; 4(5): 810-816 

8. Xuwang Chen; Erik De Clercq; Shufang Ding; Yuanyuan Li; Huiqing Liu; Jan Balzarini; Christophe Pannecouque; Xinyong Liu*. Discovery of Piperidine-Linked Pyridine Analogues as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. ChemMedChem, 2013; 8(7): 1117–1126

9. Hongfei Chen, Guoning Li, Peng Zhan, Xiuli Guo, Qian Ding, Shouxun Wang and Xinyong Liu*. Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. MedChemCommun., 2013, 4, 827-832

10. Zhenyu Li, Yuan Cao, Peng Zhan, Christophe Pannecouque, Erik De Clercq, Xinyong Liu*. Synthesis and anti-HIV evaluation of novel 1,2,4-triazole derivatives as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. Letters in Drug Design & Discovery, 2013; 10(1): 27-34

11. Zhenyu Li, Yuan Cao, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Yuemao Shen and Xinyong Liu*. Arylazolylthioacetanilide. Part 11: Design, synthesis and biological evaluation of 1,2,4-triazole thioacetanilide derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Medicinal Chemistry, 2013, 9 (6)968-973

12. Xuwang Chen, Xin Liu, Qing Meng, Ding Wang, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq and Xinyong Liu*. Novel Piperidinylamino-diarylpyrimidine Derivatives with Dual Structural Conformations as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Bioorganic & Medicinal Chemistry letter. 2013; 23(24): 6593–6597

13. Yuning Song; Peng Zhan*; Erik De Clercq; Xiao Li; Diwakar Rai; Xinyong Liu*. Multivalent agents: a novel concept for anti-HIV drug discovery. Current Medicinal Chemistry, 2013, 20(6): pp. 815-832

14. Yuning Song, Peng Zhan* and Xinyong Liu*. Heterocycle-thioacetic Acid Motif: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activities. Curr Pharm Des. 2013;19: 7141-7154

15. Yu'ning Song, Peng Zhan, Qingzhu Zhang and Xinyong Liu*. Privileged Scaffolds or Promiscuous Binders: A Glance of Pyrrolo[2,1-f][1,2,4]triazines and Related Bridgehead Nitrogen Heterocycles in Medicinal Chemistry. Current Pharmaceutical Design. 2013; 19(8): 1528-1548

16. Peng Zhan* and Xinyong Liu*. Rationally designed multitarget anti-HIV agents. Current medicinal chemistry2013; 20(13): 1743-58.

17. Xuwang Chen, Shufang Ding, Peng Zhan and Xinyong Liu*. Recent Advances of Diaryl Ether Family as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Current Pharmaceutical Design. 2013; 19(15): 2829-2838

18. Wenmin Chen, Peng Zhan, Diwakar Rai, Boshi Huang, Jiapei Yang, and Xinyong Liu*. Facile Synthesis of Derivatives of 1,1,3-Trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine: A New Heterocyclic System. Heteroatoms Chemistry. 2013,24(6):495–501

19. Dongwei Kang, Yu’ning Song, Peng Zhan, Qingzhu Zhang, Xinyong Liu*. Design, synthesis and acetylcholinesterase (AChE) inhibition assay of novel 9-(1-(substituted-benzyl) piperidin-4-yl)-2-chloro-9H-purin-6-amine derivatives. Journal of Chemistry. 2013; Volume 2013, Article ID 107302, 9 pages (http://dx.doi.org/10.1155/2013/107302) (IF=0.484)

20. SUN Sang-Dun, MI Si-Qi, YOU Jing, YU Ji-Liang, HU Song-Qing, LIU Xin-Yong*. HQSAR Study and Molecular Design of Benzimidazole Derivatives as Corrosion Inhibitors[J]. Acta Phys. Chim. Sin., 2013, 29 (6), 1192-1200

21. Liu H, Wei X, Chen L, Liu X, Li S, Liu X, Zhang X. Tetramethylpyrazine Analogue CXC195 Protects against Cerebral Ischemia/Reperfusion Injury in the Rat by an Antioxidant Action via Inhibition of NADPH Oxidase and iNOS Expression. Pharmacology. 2013;92(3-4):198-206.

2012      

1. Dongyue Li, Peng Zhan, Erik De Clercq, Xinyong Liu*. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of six representative candidates. Journal of Medicinal Chemistry, 2012, 55 (8), pp 3595–361. (IF= 5.2) (DOI: 10.1021/jm200990c)

2. Xuwang Chen, Peng Zhan, Xin Liu, Ziheng Cheng, Caicai Meng, Siyuan Shao, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*, Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry, 2012: 20 : 3856–3864

3. Wenjiun Li, Jingde Wu, Peng Zhan, Yu Chang, Christophe Pannecouque, Erik De Clercq & Xinyong Liu*. Synthesis, drug release and anti-HIV Activity of a series of PEGylated zidovudine conjugates. International Journal of Biological Macromolecules. 2012;50(4): 974-980

4. Xuwang Chen, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq and Xinyong Liu*. Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2012; 51: 60-66

5. Peng Zhan, Wenmin Chen, Zhenyu Li, Xiao Li, Xuwang Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Structure-based Bioisosterism Design, Synthesis and Biological Evaluation of Novel 1,2,4-Triazin-6-ylthioacetamides As Potent HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry Letters. 2012; 22: 7155–7162

6. Peng Zhan, Wenmin Chen, Zhenyu Li, Xiao Li, Xuwang Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Discovery of Novel 2-(3-(2-Chlorophenyl) pyrazin-2-ylthio)-N-arylacetamides As Potent HIV-1 Inhibitors Using a Structure-Based Bioisosterism Approach. Bioorganic & Medicinal Chemistry, 2012, Volume 20, Issue 23,   Pages 6795–6802

7. Xiao Li, Peng Zhan*, Hong Liu, Dongyue Li, Liu Wang , Xuwang Chen, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu*. Arylazolyl(azinyl) thioacetanilides. Part 10: Design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. Bioorganic & Medicinal Chemistry. 2012; 20: 5527-5536

8. Peng Zhan, Xuwang Chen, Dongyue Li, Zengjun Fang, Erik De Clercq, Xinyong Liu* Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and Biological Investigation of      Thiazolylthioacetamides Derivatives as A Novel Class of Potential Antiviral Agents. Archives of Pharmacal Research, 2012;Vol 35, No 6, 975-986,

9. Lijuan Deng, Xiuli Guo, Li Zhai, Yuning Song, Hongfei Chen, Peng Zhan, Jingde Wu, Xinyong Liu*. Ligustrazine derivatives. Part 4: Design, synthesis and biological evaluation of novel Ligustrazine-based stilbene derivatives as potential cerebrocardiac vascular agents. Chemical Biology & Drug Design. 2012 May ; 79 ( 5 ): 731-739 

(DOI: 10.1111/j.1747-0285.2012.01332.x)

10. Wenwen Chen, Peng Zhan, Erik De Clercq and Xinyong Liu*. Recent Progress in Small Molecule CCR5 Antagonists as Potential HIV-1 Entry Inhibitors. Current Pharmaceutical Design, 2012; 18(1): 4165-4186

11. Zhenyu Li, Peng Zhan, Lieve Naesens, Evelien Vanderlinden, Ailin Liu, Guanhua Du, Erik De Clercq and Xinyong Liu*. Synthesis and preliminary biological evaluation of 5-substituted-2-(4- substituted phenyl) benzoxazoles as a novel class of influenza virus A inhibitors. Chemical Biology & Drug Design. 2012; 79 ( 6 ): 1018-24

12. Ye Tian, Peng Zhan, Diwakar Rai, Jiyan Zhang, Erik De Clercq and Xinyong Liu*. Recent Advances in the Research of 2,3-Diaryl-1,3-thiazolidin-4-one Derivatives as Potent HIV-1 NNRTIs. Current Medicinal Chemistry, 2012; 19(13): 2026-2037.

13. Wenmin Chen, Peng Zhan, Jingde Wu, Zhenyu Li and Xinyong Liu*. The Development of HEPT-type HIV Non-Nucleoside Reverse Transcriptase Inhibitors and Its Implications for DABO Family. Current Pharmaceutical Design, 2012, 18, 4165-4186

14. Xiaofei Jiang, Peng Zhan, Xinyong Liu* & Erik De Clercq. Synthesis and Anti-HIV Activity Evaluation of 2-(5-(Naphthalen-1-yl)-1,2,3-thiadiazol-4-ylthio)-N-acetamides Derivatives. Lat. Am. J. Pharm. 2012; 31 (5): 751-755

15. Zhenyu Li, Fang Yu, Lei Cui, Peng Zhan, Shouxun Wang* and Xinyong Liu*. Ligustrazine derivatives. Part 6: Design, synthesis and evaluation of novel ligustrazine acylguanidine derivatives as potential cerebrocardiac vascular agents. Medicinal Chemistry. 2012 Jun 25. 2012;8(5):928-33.

16. Xiao Li, Peng Zhan, Erik De Clercq, Xinyong Liu*. The HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors (Part V): Capravirine and Its Analogues. Current Medicinal Chemistry, 2012; 19 ( 36): Pp.6138-6149

17. Peng Zhan, Dongyue Li, Junyi Li, Xuwang Chen and Xinyong Liu*. Benzimidazole (Benzimidazolone) Heterocycle as A Privileged Scaffold in Antiviral Agents. Mini-Review in Organic Chemistry, 2012, 9, 397-410

18. Zhai L, Zhang P, Sun RY, Liu XY, Liu WG, Guo XL.Cytoprotective effects of CSTMP, a novel stilbene derivative, against H2O2-induced oxidative stress in human endothelial cells. Pharmacol Rep. 2012, Nov;63(6):1469-80. 

2011

1. Zhang Jing, Zhan Peng, Wu Jingde, Li Zhenyu, Jiang Yan, Ge Weiying, Pannecouque C, De Clercq E, Liu Xinyong*. Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6- ((3,4-dihydroquinolin-1(2H)-yl)methyl) pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry, 2011; 19: 4366–4376

2. Mingyan Yu, Zhenyu Li, Shuai Liu, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonyl -methylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. ChemMedChem 2011; 6(5): 826–833

3. Mingyan Yu, Xinyong Liu*, Ailin Liu, Guanhua Du, Lieve Naesens, Evelien Vanderlinden, Erik De Clercq. Discovery of dihydro-alkyloxy-benzyl-oxopyrimidines as promising anti-influenza virus agents. Chemical Biology & Drug Design, 2011, 78(4): 596–602

4. Peng Zhan, Xuwang Chen, Dongyue Li, Wenwen Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Arylazolylthioacetanilide part 8.  Design, Synthesis and Biological Evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N- arylacetamides As Potent HIV-1 Inhibitors. European Journal of Medicinal Chemistry. 2011; 46 : 5039-5045

5. Zhan Peng, Li Dongyue, Chen Xuwang, Liu Xinyong*, De Clercq Erik. Functional Roles of Azoles Motif in Anti-HIV Agents. Current Medicinal Chemistry, 2011; 18(1): 29-46

6. Hongfei Chen, Peng Zhan, Xinyong Liu*. Ligustrazine derivatives. Part 5: Design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.European Journal of Medicinal Chemistry. 2011;46: 5609-5615

7. Zhan Peng, Liu Xinyong*. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010). Expert Opin. Ther. Patents (2011) ; 21(5):1-80

8. Jiang Yan, Liu Xinyong*, De Clercq Erik. New Therapeutic Approaches Targeted at the Late Stages of the HIV-1 Replication Cycle. Current Medicinal Chemistry, 2011; 18(1): 16-28

9. Mingyan Yu, Erkang Fan, Jingde Wu and Xinyong Liu*. Recent Advances in the DABOs Family as Potent HIV-1 non-Nucleoside Reverse Transcriptase Inhibitors. Current Medicinal Chemistry, 2011, 18(16): 2376-2385

10. Zhang Jing, Ge Weiying, Zhan Peng, De Clercq E, Liu Xinyong*. Retroviral Restriction Factors TRIM5α: Therapeutic Strategy to Inhibit HIV-1 Replication. Curr Med Chem. 2011; 18(17): 2649-2654.

11. Xuwang Chen, Peng Zhan, Dongyue Li, Erik De Clercq and Xinyong Liu*.Recent Advances in DAPYs and Related Analogues as HIV-1 NNRTIs. Current Medicinal Chemistry, 2011, 18, 359-376

12. Zhenyu. Li, Peng. Zhan and Xinyong Liu*. 1,3,4-Oxadiazole: A Privileged Structure in Antiviral Agents. Mini-Reviews in Medicinal Chemistry, 2011, 11: 1130-1142

13. Peng Zhan, Xuwang Chen, Xinyong Liu*, Christophe Pannecouque, Lieve Naesens, Erik De Clercq, Ailin Liu, Guanhua Du. Thiazolylthioacetamides as a Novel Class of Potential Antiviral Agents. Antiviral Research, Volume 90, Issue 2, May 2011, Page A67.

14. Wenjun Li, Peng Zhan, Jingde Wu, Yu Chang, Christophe Pannecouque, Erik De Clercq, Xinyong Liu.* Synthesis, Influence of Polymer Molecular Weight on Drug Release and Anti-HIV Activity of PEGylated AZT Conjugates. Antiviral Research, Volume 90, Issue 2, May 2011, Page A37.

15. Peng Zhan, Renzhang Yan, Xinyong Liu,*, Christophe Pannecouque, Myriam Witvrouw , Erik De Clercq, Maria Teresa Molina, Salvador Vega. Synthesis and anti-HIV activity of novel 2,4-disubstituted-7-methyl- 1,1,3-trioxo-2H,4H-pyrazolo[4,5-e] [1,2,4]thiadiazine derivatives. Drug Discoveries & Therapeutics. 2011; 5(6):279-285.2012.01.17出刊

16. Hu Song-Qing, Mi Si-Qi, Jia Xiao-Lin, Fan Cheng-Cheng, Chen Sheng-Hui, Zhang Jun, Liu Xin-Yong*. 3D-QSAR Study and Molecular Design of Benzimidazole Derivatives as Corrosion Inhibitors. Chemical Journal Of Chinese Universities. 2011, Vol. 32 Issue (10) :2402-2409

17. Yu-Ning Song, Xiu-Li Guo, Bei-Bei Zheng, Xin-Yong Liu, Xue Dong, Lu-Gang Yu, Yan-Na Cheng. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity. Toxicol. Vitro. 2011; vol. 25, no. 4, pp. 937-943, 

2010

1. Wenjun Li, Yu Chang, Peng Zhan, Na Zhang,Xinyong Liu,*Christophe Pannecouque, and Erik De Clercq. Synthesis, In Vitro and In Vivo Release Kinetics, and Anti-HIV Activity of A Sustained-Release Prodrug (mPEG-AZT) of 3’-Azido-3’-deoxythymidine (AZT, Zidovudine). ChemMedChem 2010; 5: 1893-1898.

2. Peng Zhan, Xinyong Liu*, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. 1,2,3-Thiadiazole Thioacetanilides. Part 2. Synthesis and Biological Evaluation of a New Series of 2-(4-(3,4-dichlorophenyl)-1,2,3-Thiadiazol-5-ylthio)Acetamides as Anti-HIV-1 inhibitors. Chemistry & Biodiversity. 2010; 7: 1717-1726

3.Yang Ou, Xue Dong, Xin-Yong Liu, Xian-Chao Cheng, Yan-Na Cheng, Lu-Gang Yu, and Xiu-Li Guo*. Mechanism of Tetramethylpyrazine Analogue CXC195 Inhibition of Hydrogen Peroxide-Induced Apoptosis in Human Endothelial Cells. Biol. Pharm. Bull. 2010; 33(3): 432-438

4. Ou Y, Guo XL, Zhai L, Liu XY, Cheng YN. TMPDP, a tetramethylpyrazine derivative, protects vascular endothelial cells from oxidation damage by hydrogen peroxide. Pharmazie. 2010 Oct; 65(10):755-9.

5. Peng Zhan, Hongbing Liu, Xinyong Liu*, Yan Wang, Christophe Pannecouque, Myriam Witvrouw, Erik De Clercq. Synthesis and anti-HIV activity evaluation of novel N1-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides. Medicinal Chemistry Research. 2010; 19:652–663

6. Hongfei Chen, Xinyong Liu*, Peng Zhan and Erik De Clercq. TSG101: a Novel Anti-HIV-1 Drug Target. Current Medicinal Chemistry . 2010; 17(8): 750-758

7. Peng Zhan, Xinyong Liu*, Erik De Clercq. Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm. Current Medicinal Chemistry, 2010; 17(6): 495-503 

8. Peng Zhan, Xuemei Jiang, Xinyong Liu*. Naturally Occurring and Synthetic Bioactive Molecules as Novel Non-nucleoside HBV Inhibitors. Mini-Reviews in Medicinal Chemistry. 2010 Feb;10(2):161-70.

9. Peng Zhan, Zhenyu Li, Xinyong Liu*. Cosalane and Related Analogues: A Unique Class of Anti-HIV Agents. Mini-Reviews in Medicinal Chemistry, 2010, 10, 966-976

10.Zhan Peng, Li Wenjun, Chen Hongfei and Liu Xinyong*.Targeting Protein-Protein Interactions: A    Promising Avenue of Anti-HIV Drug Discovery. Current Medicinal Chemistry, 2010; 17(6): 495-503  

  2009

1. Peng Zhan, Xinyong Liu*, Zhenyu Li, Zengjun Fang, Zhong Li, Defeng Wang, Christophe Pannecouque, Erik De Clercq. Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: synthesis and preliminary SAR studies. Bioorganic & Medicinal Chemistry, 2009; 17(16): 5920-5927. (15 August 2009).

2. Mingyan Yu, Xinyong Liu*, Zhenyu Li, Shuai Liu, Christophe Pannecouque, Erik De Clercq Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonyl methylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry, 2009;17: 7749–7754

3. Peng Zhan, Xinyong Liu*, Junjie Zhu, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. 1,2,3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluation Bioorg Med Chem. 2009; 17(16): 5733-6146

4. Peng Zhan, Xinyong Liu*, Junjie Zhu, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem. 2009; 17(16): 5775-5781.

5. Xinyong Liu*, Peng Zhan, Christophe Pannecouque, Erik De Clercq. Design, Synthesis and Anti-HIV-1 Evaluation of Novel Arylazolylthioacetanilides as Potent NNRTIS.  Antiviral Research, Volume 82, Issue 2, May 2009, Pages A44-A45

6. Peng Zhan, Xinyong Liu*, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5- ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009; 44 : 4648–4653

7.Xian-Chao Cheng, Xin-Yong Liu*, Wen-Fang Xu, Xiu-Li Guo Ning Zhang, Yuning Song Ligustrazine derivatives part 31: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents. Bioorganic & Medicinal Chemistry. 2009; 17: 3018–3024

8. Yuan Cao, Xinyong Liu* and Erik De Clercq. Cessation of HIV-1 Transcription by Inhibiting Regulatory Protein Rev-Mediated RNA Transport. Current HIV Research, 2009, 7(1):, 101-108

9. Yu Mingyan, Liu Xinyong* and Erik De Clercq. NF-κB: The Inducible Factors of HIV-1 Transcription and their Inhibitors. Mini-Reviews in Medicinal Chemistry, 2009, 9(1): 60-69

10. Jiyan Zhang, Xinyong Liu* and Erik De Clercq. Capsid (CA) Protein as a Novel Drug Target: Recent Progress in the Research of HIV-1 CA Inhibitors. Mini-Reviews in Medicinal Chemistry. 2009; Volume 9(4): April, 510-518.

11. Yan Wang, Xin-yong Liu* and Erik De Clercq. Role of the HIV-1 Positive Elongation Factor P-TEFb and Inhibitors Thereof.  Mini-Reviews in Medicinal Chemistry, 2009, 9(3): 379-385

12. Peng Zhan and Xinyong Liu*. Designed Multiple Ligands: An Emerging Anti-HIV Drug Discovery Paradigm. Curr Pharm Des. 2009; 36(15): 1893-1917

13. Peng Zhan, Zhenyu Li, Xinyong Liu* Sulfanyltriazole/tetrazoles: A Promising Class of HIV-1 NNRTIs. Mini-Reviews in Medicinal Chemistry, 2009, 9(8): 1014-1023

14. Peng Zhan, Xinyong Liu* and Zhanyu Li. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. Current Medicinal Chemistry, 2009; 16(22): 2876-2889. (August 2009)

15. Peng Zhan, Xinyong Liu*, Christophe Pannecouque, Erik De Clercq. Design Strategies of Novel NNRTIs to Overcome Drug Resistance. Current Medicinal Chemistry, 2009; 16(29): 3903-3917.

2008

1. Peng Zhan, Xinyong Liu*, Yuan Cao, Yan Wang, Christophe Pannecouque, Erik De Clercq. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett. 2008; Oct 15;18(20):5368-71.

2. Peng Zhan, Xinyong Liu* and Erik De Clercq. Recent Advances in Antiviral Activity of Benzo/Heterothiadiazine Dioxide Derivatives. Current Medicinal Chemistry, 2008; 15(15): 1529-1540.

3. Yongqiang Lin, Xinyong Liu,* Renzhang Yan, Jin Li, Christophe Pannecouque, Myriam Witvrouw and Erik De Clercq* Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides (TTDDs). Bioorganic & Medicinal Chemistry, 2008; 16 (1): 157–163

4. Xinyong Liu,* Ren-zhang Yan, Yan Wang, Peng Zhan, Christophe Pannecouque, Myriam Witvrouw, Erik De Clercq, Maria Teresa Molina and Salvador Vega. Synthesis and Anti-HIV Activity Evaluation of Novel 2,4-Disubstituted 7-Methyl-1,1,3-trioxo-2H,4H-Pyrazolo[4,5-e] [1,2,4]thiadiazines. Arch.Pharmazie, 2008; 341(4): 216-222

5. Fang Yu, Xinyong Liu,* Peng Zhan and Erik De Clercq. Recent Advances in the Research of HIV-1 RNase H Inhibitors. Mini-Reviews in Medicinal Chemistry, 2008, Nov; 8(12):1243-51

6. Xinyong Liu* , Peng Zhan, Renzhang Yan, Yongqiang Lin, Jin Li,Christophe Pannecouque  and Erik De Clercq. Design, Synthesis and Antiviral Evaluation of Novel Heterocyclic Compounds as HIV-1 NNRTIs. Drug Discov Ther 2008;2: 25-28

2007

1. Xian-Chao Cheng, Xin-Yong Liu,* Wen-Fang Xu, Xiu-Li Guo and Yang Ou. Design, synthesis and biological activities of novel Ligustrazine derivatives. Bioorganic & Medicinal Chemistry 2007; 15(10): 3315–3320

2. Jingde Wu, Xinyong Liu *, Xianchao Cheng , Yuan Cao, Defeng Wang , Zhong Li, Wenfang Xu , Christophe Pannecouque , Myriam Witvrouw and Erik De Clercq. Synthesis of Novel Derivatives of 4-Amino-3-(2-Furyl)-5-Mercapto-1,2,4-Triazole as Potential HIV-1 NNRTIs. Molecules, 2007, 12(8): 2003-2016.

3. Xin Yong LIU*, Ren Zhang YAN, Nian Gen CHEN, Wen Fang XU . Regioselective Synthesis and Anti-HIV Activity of the Novel 2- and 4-Substituted Pyrazolo[4,5-e][1,2,4]thiadiazines. Chin. Chem. Lett. 2007;18: 137-140

4. Xin-Yong Liu*, Xian-Jun Qu, Wei Tang. China-Japan enhance joint research cooperation for drug discoveries and development: News from CJMWDDT 2007 in Jinan, China . Drug Discov Ther 2007;1(1):1

2006

1. Xinyong Liu* Niangen Chen, Renzhang Yan, Wenfang Xu, Maria Teresa Molina, and Salvador Vega Regioselective Synthesis of the Novel N4-Substituted Pyrazolo[4,5-e][1,2,4] thiadiazines as Potent HIV-1 NNRTIs. Heterocycles, 2006; 68(6): pp.1225-1232

2. Xinyong Liu*, Renzhang Yan, Niangen Chen, Wenfang Xu, Maria Teresa Molina and Salvador Vega. Regioselective Synthesis of Novel N2- and N4-Substituted 7-Methylpyrazolo [4,5-e] [1,2,4]thiadiazines, Molecules, 2006, 11: 827-836

3. Xianchao Cheng, Xinyong Liu*, Wenfang Xu. Synthesis of Novel Ligustrazine Derivatives as Potential Platelet Aggregation Inhibitors. Chinese Chemical Letters 2006; Vol. 17, No. 10, pp 1317-1320

4. Xian-chao Cheng, Xin-yong Liu* and Wen-fang Xu .The preparation of novel ligustrazine derivatives as potential cerebrocardiac vascular agents. Journal of Chemical Research, 2006; September, 577–579

5. Ren-Zhang Yan, Xin-Yong Liu*, Wen-Fang Xu, Christophe Pannecouque1, Myriam Witvrouw, and Erik De Clercq. Synthesis and Anti-HIV Evaluation of the Novel 2-(m-Chlorobenzyl)-4- substituted-7-methyl-1, 1, 3-trioxo-pyrazolo[4,5-e][1, 2, 4]thiadiazines. Arch Pharm Res, 2006; 29, No 11, 957-962

2005-2003

1. Xinyong Liu*, Niangen Chen, Yinzhang Yan, Wen-fang Xu. Design and Synthesis of N4-Substituted Pyrazolo[4,5-e][1,2,4] Thiadiazine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Chinese Journal of Organic Chemistry. 2005; Vol. 25, Suppl., 701

2. Xianchao Cheng, Xinyong Liu* Wenfang Xu. Recent advances in the structural modification of ligustrazine; cerebro- and cardiovascular activity of ligustrazine derivatives. Drugs of the Future, 2005; 30(10): 1059.

3. Xin Yong Liu*, Wen Fang Xu, Jing De Wu. Synthesis of 4-Amino-5-furyl-2-yl-4H-1, 2, 4-triazole-3-thiol Derivatives as a Novel Class of Endothelin(ET) Receptor Antagonists. Chin Chem. Letter (CCL); 2003, 14(8):790-793       

4. Zeng Bao-Shan, Chen Min-Bo*, Dong Xi-Cheng, Liu Xin-Yong*. q2 Guided Conformation Selection Approach of CoM FA for HIV-1 RT Inhibitors. Acta Chemica Sinica, 2003; 61(7): 1121-1128

5. Xinyong Liu*, Zhang Rui and Wenfang Xu. Synthesis of The Novel Liqustrazine Derivatives and Their Protective Effect on Injured Vascular Endothelial Cell Damaged by Hydrogen Peroxide.  Bioorg. Med. Chem. Letter; 2003; 13: 2123-2126

 



版权所有:山大药学院 Copyright 2007-2013
    地址:济南市文化西路44号 电话:0531-88382017 传真:0531-88382548 E-mail:pharma@sdu.edu.cn